Improved estimates of COVID-19 correlates of protection, antibody decay and vaccine efficacy waning: a joint modelling approach 3 Daniel J. Phillips¹, Maria D. Christodoulou¹, Shuo Feng^{2,3}, Andrew J. Pollard^{2,3}, 4 Merryn Voysey^{2,3}, and David Steinsaltz¹ ¹Department of Statistics, University of Oxford, Oxford, UK ²Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK ³NIHR Oxford Biomedical Research Centre, Oxford, UK July 2, 2024 10 Abstract 11 Reliable estimation of the relationship between COVID-19 antibody levels at the time of 12 exposure and the risk of infection is crucial to inform policy decisions on vaccination regimes. 13 We fit a joint model of anti-spike IgG antibody decay and risk of COVID-19 infection to data 14 from a randomized efficacy trial of the ChAdOx1 nCoV-19 vaccine. Our model improves 15 upon previous analyses by accounting for measurement error, decay in antibody levels and 16 variation between different individuals. We estimated correlates of protection, antibody 17 decay, and vaccine efficacy waning. Increased anti-spike IgG antibody levels at the time of 18 exposure correlate with increased vaccine-induced protection. We estimated vaccine efficacy 19 against symptomatic COVID-19 infection of 88.1% (95% CrI: 77.2, 93.6) at day 35, waning 20 to 60.4% (44.6, 71.0) at day 189 since the second dose. We report that longer intervals 21 between the first and second vaccine dose give lasting increased protection, and observe 22 lower efficacy in individuals aged ≥ 70 years from around 3 months after second dose. Our 23 methods can be used in future vaccine trials to help inform the timings and priority of 24 vaccine administration against novel diseases. 25

²⁶ Introduction

27 Correlates of protection, i.e. immune markers which relate to the risk of a disease outcome, are 28 crucial to understanding the biological mechanisms for protection against infection after a given

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²⁹ treatment. Most studies consider how immune responses at a fixed time soon after treatment

 $_{30}$ correlate with risk of a disease outcome. However, it is the immune markers present at the time

31 of exposure which protect against infection. Modelling immune levels over time and relating

 $_{\rm 32}$ $\,$ these to vaccine-induced protection, allows a clearer understanding of the relationship between

immune responses and protection, and avoids potential biases due to waning of immune levels

 $_{34}$ between the measurement and exposure. This further provides a natural framework to investi-

 $_{\tt 35}$ $\,$ gate the effect of factors such as age, comorbidities and dose schedules on immune response and

 $_{\rm 36}$ $\,$ protection, and to estimate changes in levels of protection over time.

³⁷ In response to the COVID-19 pandemic, the (Oxford-AstraZeneca) ChAdOx1 nCoV-19 (AZD1222)

vaccine has been widely administered in the UK and worldwide, alongside other COVID-19 vac-

39 cines. Binding and neutralising antibodies have been shown to be correlates of protection for

⁴⁰ ChAdOx1 nCoV-19 [1, 2] and other COVID-19 vaccines [3, 4, 5, 6, 7]. These studies all considered

⁴¹ how initial peak antibody responses correlate with the risk of future COVID-19 infection, as this

42 is the timepoint most relevant for vaccine licensure. If used to understand how antibody levels
43 at the time of exposure relate to risk of infection, the above approaches may be biased, as they

44 do not account for the waning of antibody levels between the time of the antibody measurement

⁴⁵ and exposure [8]. Other studies focussed on the relationship between antibody levels at exposure

and the risk of subsequent infection [9, 10, 11]. Wei et al. (2022, 2023) used observational data

to estimate how risk of infection after vaccination relates to a recent antibody measurement [9, 10]. However the use of observational data may cause their results to be biased. Follmann et

⁴⁹ al. (2023) modelled antibody decay over time after vaccination, relating the risk of infection to

⁵⁰ the predicted antibody level at the time of exposure [11]. However, Follmann et al. assume the

⁵¹ same rate of decay for all individuals, which may decrease power and lead to bias. Further, all

⁵² the above studies on correlates of protection use only one antibody measurement per individual.

⁵³ This means they are unable to account for measurement error, which will likely introduce bias

to the results [12].

Vaccine efficacy (VE) has been shown to wane over time after two doses of the ChAdOx1 nCoV-55 19, BNT162b2, and mRNA-1273 vaccines in the UK and elsewhere, against the Alpha variant 56 [13] and the Delta variant [13, 14, 15, 16, 17, 18]; as well as after a third booster dose [18, 19]. 57 These studies all use observational data, in test-negative or cohort designs, which may intro-58 duce bias due to unmeasured confounders affecting both the probability of vaccination and of 59 the clinical outcome (e.g. infection) [20, 21]. Randomised controlled trials are free of such bias, 60 however sample sizes tend to be much smaller, restricting power for analysis of efficacy waning. 61 Including antibody data in a model for vaccine efficacy waning may increase the power of the 62 analysis [22, 8]. 63

Joint models of longitudinal and time-to-event data are a powerful tool to investigate how longitudinal biomarker trajectories relate to the risk of health- or disease-related events [8]. The

method has been applied to data on various diseases, especially disease progression in HIV/AIDS

⁶⁷ [23] and cancer trials [8]. See Ibrahim, Chu and Chen (2010) [8] for an introductory review, and

Gould et al. (2015) [24] for a review with more detail on implementation methods and packages. 68

Joint modelling has been shown to reduce bias and increase power in estimating the relation-69

ship between a longitudinal biomarker and clinical event [8, 25], when compared with methods 70

which use observed biomarkers directly to predict risk. This is because the approach accounts for 71

biomarker measurement error, as well as changes in the biomarker over time. Joint models have 72

been applied to understand how viral load [26] and changes in biomarkers [27] relate to risk of 73 mortality in COVID-19 patients, and to predict their risk of mortality from biomarker data [28].

They have also previously been used to understand how vaccine-induced immune responses relate 75

to risk of AIDS/death in HIV patients [29], and risk of relapse/death in cancer patients [30]. We 76

are not aware of any previous work applying joint modelling to understand how vaccine-induced 77

responses relate to risk of infection with COVID-19 or any other infectious disease. 78

We implement a two-stage joint model for COVID-19 antibody decay and risk of COVID-19 in-79

fection after vaccination using multiple imputation [31]. Our model accounts for antibody decay 80 over time, individual differences in decay rates and antibody measurement error. We apply our 81 model to data from a randomised vaccine efficacy trial of two doses of the ChAdOx1 nCoV-19 82 vaccine [32, 33] to investigate three main outcomes (COV002). Firstly, we model the waning 83 of anti-spike IgG antibody levels over time. Secondly, we estimate correlates of protection -84 the relationship between anti-spike IgG antibody levels at the time of exposure and the risk of 85 COVID-19 infection. Thirdly, we estimate waning vaccine efficacy over time, and investigate 86

covariate effects on antibody and vaccine efficacy waning. 87

Results 88

74

We used data from the COV002 trial [32, 33] to assess antibody waning, vaccine efficacy (VE) 89 waning, and correlates of protection against any COVID-19 infection and symptomatic COVID-90 19 infection at the time of exposure. COV002 is a randomized single-blind vaccine efficacy trial of 91 the ChAdOx1 nCoV-19 vaccine, conducted in the United Kingdom. Participants were considered 92 at risk of infection from 21 days after their second dose of vaccine, over a period from 18 July 93 2020 to 30 June 2021. This analysis includes 4605 ChAdOx1 nCoV-19 vaccinated individuals 94 (vaccine arm) and 4423 individuals who received a MenACWY control vaccine (control arm). 95 Supplementary Table 1 summarises baseline characteristics for the vaccine and control arm. 96 Supplementary Fig. 1 summarises exclusions for the two groups. In the vaccine and control arm, 97 207 (4.5%) and 377 (8.5%) tested positive for COVID-19 respectively, and 71 (1.5\%) and 217 98 (4.9%) were primary symptomatic COVID-19 cases respectively (Supplementary Table 1). qq

Waning anti-spike IgG antibody levels 100

Blood samples were taken at study visits in windows centred at 28 days, 90 days and 182 days 101 after the second dose. We refer to these as the PB28 (post-boost + 28 days), PB90 and PB182 102 study visits respectively. Samples were sent for anti-spike IgG antibody testing by case-cohort 103

sampling. Samples taken after a reported COVID-19 infection were excluded from analysis. Ob-104 served antibody responses differed between those who did not return a positive COVID-19 test 105 during the at risk period (non-cases), all who later tested positive (cases) and those who tested 106 positive with primary symptoms (symptomatic cases). At the PB28, PB90 and PB182 study vis-107 its, antibody observations were available from 1155 (26.3%), 519 (11.8%), 58 (1.3%) non-cases, 108 173 (83.6%), 64 (30.9%), 1 (0.5%) cases, and 59 (83.1%), 23 (32.4%), 1 (1.4%) symptomatic 109 cases respectively (Supplementary Table 2). At the PB28, PB90 and PB182 study visits, ob-110 served antibody levels had a median (interquartile range (IQR)) of 219 (119, 383), 115 (66, 206), 111 65 (45, 117) BAU/mL among non-cases, 197 (103, 322), 93 (47, 168), 30 (NA – only one measure-112 ment) BAU/mL among cases and 165 (100, 276), 78 (62, 178), 30 (NA - only one measurement) 113 BAU/mL among symptomatic cases respectively. Fig. 1a shows the observed antibody levels 114 against time, plotted on a log scale. The figure indicates (i) log antibody levels decay linearly, 115 (ii) different individuals have different levels of initial log antibody response and (iii) may have 116 different rates of decay. 117 In total, 923 antibody observations were available from 853 (18.5%) control participants. Among 118

control participants, antibody levels had a median (IQR) of 0.3 (< 0.21 (lower limit of quantifica-
tion (LLOQ)), 0.5) BAU/mL (Supplementary Fig. 2, Supplementary Table 2). In our subsequent
modelling we did not model antibody levels in the control arm, nor include an antibody effect
on risk for control participants.

We modelled the decay in antibody levels over time among the vaccinated participants, allowing different initial antibody responses and rates of decay for different individuals (Methods). Predicted median anti-spike IgG levels at day 28, 90 and 182 were 217 (95% credible interval (CrI): 208, 227), 119 (113, 126), 49 (45, 54) BAU/mL respectively. The median half-life of the anti-spike IgG antibody levels was 74 days (95% CrI: 69, 79). Fig. 1b shows the predicted antibody levels over time for each individual in the study on a log-scale.

Predicted antibody levels and rates of decay varied among individuals. The estimated 25% and 129 75% quartiles for the antibody response at day 28 were given by 124 (95% CrI: 117, 130) and 130 378 (359, 398) respectively (Supplementary Fig. 9). The half-life of the antibody levels among 131 individuals in the study had an estimated 25% and 75% quartile of 62 days (95% CrI: 58, 67) 132 and 87 days (79, 96). Among non-cases, the median (IQR) predicted anti-spike IgG level at day 133 28 was 219 (95% CrI: 209, 229), among cases 192 (175, 209) and among symptomatic cases 169 134 (146, 196). The median half-life was 74 (95% CrI: 70, 79) among non-cases, 60 (52, 69) among 135 cases and 54 (45, 69) among symptomatic cases. 136

¹³⁷ Correlates of protection

We modelled how the protective effect of the vaccine relates to the modelled antibody levels over time. The instantaneous risk of COVID-19 infection for a given individual in our model depends on: (i) the current background levels of COVID-19, (ii) covariates which may affect risk of COVID-19 infection (iii) the modelled level of antibody 7 days prior, and (iv) a non-antibody




Figure 1: Observed and estimated anti-spike IgG antibody levels over time since vaccination. (a) Observed anti-spike IgG antibody levels over time since vaccination. Each point represents an observation, and consecutive observations from the same individual are connected by a line. Black, blue and red points represent observations taken at the PB28, PB90 and PB182 study visits respectively. The dashed horizontal line shows the lower limit of quantification (LLOQ), 0.21 BAU/mL. (b) The posterior mean estimate of the latent true antibody levels over time for each individual. Note 1b represent estimates of the latent true antibody levels which are free from measurement error, whereas the observed antibody levels in 1a are measured with error, so show higher variability.

¹⁴² effect due to vaccination (Methods). We assume a 7 day gap between initial exposure to COVID-

¹⁴³ 19 and a positive test being reported.

¹⁴⁴ Supplementary Fig. 3-6 show an estimate of the baseline hazard of infection during the trial

period, the number of participants at risk over time since vaccination, the timings of antibody

samples, and the timings of COVID-19 infections in the study respectively. Differences in baseline
risk of infection due to different covariates are reported in Supplementary Fig. 7 and Supplementary

148 tary Table 6.

We assessed how predicted antibody level at the time of exposure correlates with protection 149 against COVID-19 infection. Predicted anti-spike IgG titer was correlated with protection. Fig. 150 2 shows the relationship between VE and anti-spike IgG antibody level predicted by our model. 151 Anti-spike IgG values of 10, 100 and 1000 BAU/mL represent the 0.0%, 17.7% and 97.1% quan-152 tiles of predicted antibody levels at day 28 post second dose, and the 5.4%, 78.1% and 100% 153 quantiles of predicted levels at day 182 respectively. At anti-spike IgG levels of 10, 100 and 154 1000 BAU/mL, the VE against symptomatic infection was 36.1% (95% CrI: -20.7, 63.0), 76.1%155 (64.4, 88.7), 100% (97.3, 100) respectively. We observe lower efficacy against any COVID-19 156 infection at the same antibody levels, 14.3% (95% CrI: -22.5, 38.1), 55.3% (44.4, 66.3), 99.9% 157 (96.2, 100) respectively. Vaccine efficacy of 50%, 70%, and 90% against symptomatic infection 158 was achieved at anti-spike IgG levels of 32 (95% CrI: 0, 57), 78 (51, 139), 182 (105, 507) BAU/mL 159 respectively (Supplementary Table 7). Against any COVID-19 infection higher antibody levels 160 were required for the same efficacy, 84 (95% CrI: 59, 125), 156 (109, 285), 311 (194, 662) BAU/mL 161 respectively. 162

¹⁶³ Waning vaccine efficacy

As the antibody levels decayed over time, the vaccine efficacy waned. Fig. 3 shows the mean VE over time since the second dose, averaged over all individuals in the study. We report efficacy 7 days after the planned study visits. The efficacy at day 35 after the second dose was estimated to be 88.1% (95% CrI: 77.2, 93.6) against symptomatic infection and 76.0% (64.3, 83.7) against all COVID-19 infection. The efficacy waned to 77.7% (68.5, 84.1) and 60.8% (51.4, 68.4) at day 97 and 60.4% (44.6, 71.0) and 39.6% (26.1, 50.2) at day 189 against symptomatic infection and all COVID-19 infection respectively.

Levels of protection varied based on individual antibody responses. At day 28, the predicted 25%, 171 50% and 75% antibody quantiles were 124 (95% CrI: 117, 130), 217 (208, 227), 378 (359, 398) 172 BAU/mL respectively (Supplementary Fig. 9). The corresponding VE quantiles at day 35 against 173 symptomatic infection were 81.4% (95% CrI: 68, 93.7), 93.1% (76.6, 99.4), 98.8% (85.2, 100), and 174 against any COVID-19 infection were 62.1% (49.7, 75.1), 80.5% (63.1, 92.7), 93.8% (77.1, 99.1) 175 (Supplementary Fig. 8). At day 182, the respective antibody quantiles were 26 (23, 29), 49 176 (45, 54), 91 (82, 102) BAU/mL, and corresponding VE quantiles were 46.3% (16.1, 65.3), 58.8% 177 (44.9, 69.5), 73.9% (62.6, 85.6) against symptomatic infection, and 23.6% (-0.8, 41.5), 35.5% 178 (21.6, 47.1), 52.5% (42.1, 62.3) against any COVID-19 infection. 179




Figure 2: Vaccine efficacy as a function of anti-spike IgG levels. VE (%) plotted against anti-spike IgG antibody levels (BAU/mL) on a log scale. The red and blue curves and shaded regions show the posterior median and associated 95% credible intervals for VE against primary symptomatic COVID-19 infection, and against all NAAT+ positive tests respectively. The vertical dotted line shows the lower limit of quantification (LLOQ), 0.21 BAU/mL. The blue histogram shows the distribution of the predicted anti-spike IgG antibody levels in the study at 28 days since the second dose, and the green histogram at 182 days post second dose. The two histograms overlap. The heights of the histograms are not to scale.




Figure 3: Vaccine efficacy as a function of time since second dose vaccination. The red curve and shaded region shows the posterior median and associated 95% credible interval for VE against symptomatic COVID-19 infection, and the blue curve and shaded region shows the posterior median and 95% credible interval for VE against all positive COVID-19 tests.

¹⁸⁰ Covariate effects on antibody levels and vaccine efficacy waning

We report the estimated effects of different covariates on initial antibody response, subsequent 181 antibody decay, and vaccine efficacy over time. Our model predicts a large decrease in antibody 182 levels for those with shorter intervals between the first and second dose (Fig. 4, Supplementary 183 Table 5). Compared with participants with dose intervals of ≥ 12 weeks, participants with dose 184 intervals of 9-11 weeks, 6-8 weeks and <6 weeks have predicted anti-spike IgG antibody levels 185 83% (95% CrI: 74, 93), 70% (61, 81), 51% (43, 61) as high respectively, at 28 days after the 186 second dose. We also predict a larger antibody response due to receiving a low dose as the 187 first dose compared with a standard dose, although 95% credible intervals contain a null effect. 188 We predict lower antibody responses at 28 days after the second dose in older age groups, and 189 among healthcare workers. Higher antibody responses are predicted in females than males, and 190 in non-white participants. Shorter half-lives of antibody levels are predicted for females, and 191 individuals with a BMI > 30 (Fig. 4, Supplementary Table 5). 192

To consider covariate effects on VE, we compare with reference values of age 18-55 years, female, 193 white ethnicity, no comorbidities, BMI $<30 \text{ kg/m}^2$, ≥ 12 week interval between first and second 194 dose, non-HCW (non-healthcare worker), and receiving a standard dose as their first dose. We 195 then vary each of these covariates and plot VE for each covariate combination against symp-196 tomatic infection in Fig. 5 and against all COVID-19 infection in Supplementary Fig. 10. We see 197 that shorter intervals between first and second dose predict a lower VE throughout the study. 198 VE against symptomatic infection at day 35, 97 and 189 was 93.1% (CrI: 81.6, 97.6), 85.0% 199 (72.1, 92.1) and 68.7% (53.2, 77.4) respectively for a reference individual (with ≥ 12 week inter-200 val), compared with 83.2% (71.6, 91.0), 71.7% (58.2, 80.4) and 55.0% (27.0, 69.2) respectively 201 for an individual with <6 week interval. We also observe a lower efficacy after around 90 days 202 in individuals aged 70 years or older compared with the 18-55 and 56-69 years age groups. VE 203 for an individual aged 70 years or older at day 35, 97 and 189 was 90.7% (78.8, 96.4), 79.2%204 (67.5, 88.2) and 59.9% (35.2, 72.7) respectively, compared with a reference individual above. 205





Figure 4: Covariate effects on anti-spike IgG antibody levels. The multiplicative effects on (a) day 28 anti-spike IgG antibody levels and (b) half-life of anti-spike IgG antibody decay for different covariates. The effects are plotted on a log scale. These results are also given in Supplementary Table 5.



Days since second dose vaccination

Figure 5: Vaccine efficacy against symptomatic COVID-19 infection plotted against time since vaccination for different covariate combinations. The black lines represent an individual with reference covariates: age 18-55, female sex, white ethnicity, no comorbidities, $BMI < 30 \text{ kg/m}^2$, ≥ 12 week interval between first and second dose, non-HCW (healthcare worker), and receiving a standard dose as their first dose. All other coloured lines represent an individual with one of the above covariates changed from these reference values. The solid lines show posterior medians and dashed lines 95% credible intervals. "HCW < 1 COVID" refers to a healthcare worker facing <1 COVID-19 patient per day, "HCW ≥ 1 COVID" refers to a healthcare worker facing ≥ 1 COVID-19 patient per day.

| Paper | Antibody type | Vaccine | Doses | Dominant variant | Timing of antibody effect on risk [‡] | Accounts for measurement error | Accounts for antibody waning between measurement and exposure | Accounts for individual variation in slopes | Randomised vaccine /control assignment | Unvaccinated baseline comparator | Location of result in paper | Endpoint | Antibody level (BAU/mL unless otherwise stated) | Vaccine efficacy (%) | Our result |
|--------------------------------|--|---|---|---|---|--------------------------------------|---|--|---|---|-----------------------------------|---|--|---|---|
| Feng et al. (2021) [1] | Spike nAb* others* | ChAdOx1 [†] | Two doses | Pre-Delta (Alpha B.1.1.7 and B.1.177) | Peak (~28 (14-42) days post second dose) | x | x | x | V | V | Table 2 (Fig. 4a) | Symptomatic Asymptomatic* | 29 (NC, 83) 54 (NC, 143) 113 (NC, 245) 264 (108, 806) 899 (369, NC) [§] | 50% 60% 70% 80% 90% | 32 (0, 57) 52 (0, 82) 78 (51, 139) 117 (76, 266) 182 (105, 507) BAU/mL |
| Benkeser et al. (2023) [2] | Spike nAb [*] others [*] | $ChAdOx1^{\dagger}$ | Two doses | Pre-Delta (B.1.2) | Peak (~28 days post second dose) | x | x | x | V | V | In text and Fig. 5a | Symptomatic | 21 100 1000 | $\begin{array}{c} 21.1\% \ (-361, \ 79.3) \\ 62.9\% \ (-55.0, \ 85.7) \\ 88.1\% \ \ (52.0, \ 97.0) \end{array}$ | 43.3% (6.6, 64.6) 76.1% (64.4, 88.7) 100% (97.3, 100) VE (%) |
| Wei et al. (2022) [9] | Spike | ChAdOx1 [†] BNT162b2 [*] | Two doses | Delta (B.1.617.2) | Exposure (21-59 days prior to infection) | x | x | x | x | V | Fig. 4c | Symptomatic Any infection* Ct<30* | 25 100 400 | $\begin{array}{c} 55\% \ (40,\ 65) \\ 68\% \ (59,\ 75) \\ 82\% \ (74,\ 88) \end{array}$ | 45.8% (14.5, 65.2) 76.1% (64.4, 88.7) 99.0% (86.2, 100) VE (%) |
| Wei et al. (2023) [10] | Spike | ChAdOx1 [†] BNT162b2 [*] | Two doses plus booster or infection | Omicron BA.4/5 (B.1.1.529) | Exposure (21-59 days prior to infection) | x | x | x | x | Compared with vaccine non-responders¶ | Supp. Fig. 1 and Fig. 1a | Any infection Symptomatic [*] Ct<30 [*] | 920 (766, 1092) 1740 (1502, 2331) 3680 (2831, 4500) | 50% 70% 80% | 32 (0, 57) 78 (51, 139) 117 (76, 266) BAU/mL |
| Follmann et al. (2023) [11] | nAb | mRNA-1273 | Two doses | Pre-Delta period | Exposure (7 days prior to infection) | x | V | x | V | V | In text and Fig. 2 | Symptomatic | 100 IU50/mL 1000 IU50/mL (Neutralising antibody) | 93% (91, 95) 97% (95, 98) | No comparison possible |
| Our analysis | Spike | $ChAdOx1^{\dagger}$ | Two doses | Pre-Delta (Alpha B.1.1.7 and B.1.177) | Exposure (7 days prior to infection) | √ | V | ~ | V | v | In text and Fig. 2 | Symptomatic Any infection* | 10 100 1000 | $\begin{array}{c} 36\% \ (-21, \ 63) \\ 76\% \ \ (64, \ 89) \\ 100\% \ \ (97, \ 100) \end{array}$ | |

Table 1: Comparison of methods and results with previous correlates of protection studies

We include studies of the ChAdOx1 nCoV-19 vaccine, as well as studies which relate antibody levels at the time of exposure to risk of infection, for comparison. Results are given with 95% confidence intervals or credible intervals, depending on the paper. Some results show the antibody level required for a certain vaccine efficacy, others show the vaccine efficacy associated with a certain antibody response. *We do not report these results here, see the original paper. † ChAdOx1 refers to the ChAdOx1 nCoV-19 vaccine in this table. ‡ Some studies relate antibody levels at the peak response after vaccination to risk of infection, others relate antibody levels at exposure to infection. This column denotes the time at which the antibody measurement was taken which relates to risk of infection, or the time at which the modelled antibody level relates to risk of infection (for analyses which use an antibody measurement directly or model antibody levels over time respectively). $^{\$}NC =$ not computed (beyond data range). [¶]Wei et al. (2023) define vaccine non-responders to be vaccinated individuals with a recent anti-spike IgG measurement of 16 BAU/mL.

206 Discussion

We estimated correlates of protection, vaccine efficacy waning and antibody waning after two 207 doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine, against any COVID-19 infection and symp-208 tomatic COVID-19 infection. We fit a two-stage joint model using multiple imputation [31] which 209 accounts for antibody waning and measurement error, allowing the risk of infection to depend 210 on the estimated anti-spike IgG level at exposure. We found antibody levels are predictive of 211 vaccine efficacy, which wanes over time, but continues to protect against the Alpha variant 209 212 days after the second dose. We estimated mean VE against symptomatic infection to be 88.1%213 (95% CrI: 77.2, 93.6) at day 35, waning to 60.4% (44.6, 71.0) at day 189 (Results). There was 214 noticeable variation in VE between individuals, depending on the strength of their antibody 215 response. We reported that a longer interval between the first and second vaccine dose gives 216 improved protection, adding to existing evidence [34, 35, 9]. VE after 3 months since second 217 dose vaccination was also lower in individuals aged 70 years or older than in younger age groups. 218 We estimated "exposure-proximal" correlates of protection by relating modelled antibody levels 219 at the time of exposure to the risk of COVID-19 infection. This approach more closely matches 220 the biological mechanism than relating peak antibody levels to risk of infection. Table 1 com-221 pares our methods and results with previous studies of COVID-19 correlates of protection. As 222 outlined in the introduction, previous analyses have demonstrated both binding and neutralising 223 antibodies measured at a fixed time after vaccination are associated with VE against COVID-19, 224 including a study analysing data from the same COV002 trial [1], an analysis of data from a 225 different trial of the ChAdOx1 nCoV-19 vaccine [2], as well as analyses of trials of other vac-226 cines [3, 4, 5], and booster doses [6, 7]. These studies compared peak antibody levels and risk 227 of infection, and generally report wide confidence intervals due to a lack of power. They did 228 not account for antibody waning between the time of measurement and exposure, which may 229 introduce a bias^[8]. Other studies have estimated correlates of protection by relating antibody 230 levels at the time of exposure to the risk of infection, by using a recent antibody measurement 231 [9, 10], or a model to predict antibody decay over time [11]. However the studies using a recent 232 antibody measurement (Wei et al. 2022, 2023) used observational data from a cohort study, and 233 did not account for antibody waning between measurement and exposure, which may introduce 234 bias [9, 10]. The study modelling antibody levels over time (Follmann et al. 2023) assumed the 235 rate of antibody decay to be the same for all individuals in the study, which may introduce 236 bias if it decay rates vary [11]. All the above studies only used one antibody measurement per 237 individual, meaning they are unable to account for measurement error in the antibody levels, 238 which may bias the analysis [12]. None of these prior studies relate protection against COVID-19 239 infection to antibody levels at the time of exposure while also accounting for measurement error 240 or variation between individual rates of antibody level decay. 241

We used a two-stage joint model to relate modelled antibody levels at the time of exposure to the risk of infection. Joint models have been shown to reduce bias and improve power in estimating the relationship between longitudinal outcomes (e.g. antibody levels) and the time

until an event (e.g. infection) [36, 25], as well as in estimating the trajectory of the longitu-245 dinal variable (antibody levels) [36]. Moreno-Bentacur et al. (2018) previously found using a 246 multiple imputation-based joint model reduced bias, when compared with using the longitudi-247 nal observations directly to predict risk [25]. We include multiple antibody measurements per 248 individual where available, allowing us to account for measurement error and variation between 249 individual rates of decay. We further account for the informative censoring of antibody data 250 after infection. We are not aware of any previous work applying joint modelling to understand 251 how vaccine-induced immune responses relate to risk of infection for COVID-19 or any other 252 infectious disease. 253

We observe higher vaccine efficacy with much lower uncertainty at the same level of antibody, 254 compared with the studies relating peak antibody levels to risk of infection [1, 2] (Table 1). The 255 lower efficacy these studies report is likely due to antibody waning between the measurement 256 and exposure, meaning higher initial antibodies would be required to give the same protection 257 at exposure. These models also do not account for measurement error, which introduces noise to 258 the data, likely causing the observed protective effect to be diluted [12]. Our results are broadly 259 similar to those of Wei et al. (2022) who relate antibody levels at the time of exposure to risk of 260 infection [9] (Table 1). Much higher antibody levels are required for similar levels of protection 261 against the Omicron variant [10]. We are unable to compare with the results of Follmann et al. 262 (2023), as their paper uses neutralising antibodies, whereas we use anti-spike IgG [11]. 263

We estimated the peak antibody response at 28 days after ChAdOx1 nCoV-19 vaccination, the 264 subsequent rate of decay, and associated covariate effects. Table 2 compares our methods and 265 results with previous studies. Wei et al. (2022) previously used a similar approach applied to non-266 randomised cohort data [9]. Their model does not account for the aforementioned informative 267 censoring of antibody measurements, which may lead to bias [36]. This is because individuals 268 with lower antibody levels will be more likely to test positive for COVID-19, after which anti-269 body measurements will be excluded from analysis. Thus individuals with lower antibody levels 270 are less likely to have antibody measurements available, introducing informative missing data, 271 which should be accounted for. However, as cases are rare in the population, this bias may be 272 small. We estimated higher peak anti-spike IgG levels than Wei et al. study [9] (Table 2). This 273 may be partly due to differences in the populations enrolled in the two studies. Our estimated 274 half-life of antibody decay was broadly similar to previous results (Table 2). We observed indi-275 viduals with longer dose intervals had higher peak antibody levels (Fig. 4, Supplementary Table 276 5), as previous studies have reported [35, 34, 9]. We also observed higher peak antibody levels 277 in younger individuals (18-55 vs >70), non-healthcare workers and non-white participants. The 278 higher peak in non-white participants was also observed by Wei et al. (2022) [9], however there is 279 no consensus on the effect of age and healthcare work on antibody levels (Table 2). We reported 280 slower antibody decay in participants with a $BMI < 30 \text{kg/m}^2$ (Fig. 4, Supplementary Table 5), 281 and detected slightly slower antibody decay in males, however this does not translate to a no-282 ticeable difference in VE waning (Fig. 5, Supplementary Fig. 10). Neither of these differences 283

have been reported elsewhere and it is unclear if they represent true effects. We did not detect
the other effects on peak antibody observed by Wei et al. (2022) [9].

We reported predicted vaccine efficacy over time since second dose from our model, calculated 286 from randomised controlled trial data. One previous analysis considered waning after a first 287 dose of ChAdOx1 nCoV-19 [34], however the analysis was underpowered. Apart from this, we 288 are not aware of any studies of ChAdOx1 nCoV-19 vaccine efficacy waning evaluated on ran-289 domised data. Table 3 and Supplementary Table 8 compare our methods and results to previous 290 studies of waning vaccine efficacy, with a focus on studies of the ChAdOx1 nCoV-19 vaccine. 291 These studies all use non-randomised observational data, including test-negative design studies 292 [13, 14, 15, 18], and cohort studies [37, 15, 16, 17]. The test-negative design may introduce bias 293 due to unmeasured differences in health-seeking behaviour between the vaccinated and unvac-294 cinated arms, likely reducing the observed VE [20, 21]. Results may also not carry over to the 295 wider population, as those included in the study will likely test more frequently. Cohort studies 296 are similarly vulnerable to biases due to unmeasured confounding causing differences in risk of 297 infection between the unvaccinated and vaccinated populations. Such biases may increase over 298 time, as the unvaccinated group are increasingly unvaccinated by choice, which may correlate 299 with fewer health-seeking behaviours. Further, accumulation of more undetected infections in 300 the unvaccinated arm may lead to VE waning to appear greater, due to the so-called depletion of 301 susceptibles bias [38]. This bias may occur in randomised or observational data. Asymptomatic 302 swabbing may negate this bias by increasing the proportion of infections which are detected. 303 Rates of asymptomatic swabbing were high in our study [39], with around 75% of participants 304 returning an asymptomatic test on a given week. Rates of asymptomatic swabbing were likely 305 much lower in the other studies, where participants were not encouraged to swab weekly. 306

Our analysis has some advantages over these methods. The data comes from a randomised 307 single-blinded controlled trial, avoiding the potential biases of an observational cohort study 308 and a test-negative case-control study. We model antibody waning and vaccine efficacy waning 309 jointly over time, which may improve the efficiency of our estimates [22]. Further, the length 310 of follow-up in our study after second dose was relatively long at over 29 weeks. However, the 311 sample size of our data is much smaller than most of these studies, hence we report wider CrIs. 312 Table 3 and Supplementary Table 8 compare our methods and results to previous studies of vac-313 cine efficacy waning against different variants. Results from previous studies varied by variant, 314 with lower efficacy generally predicted against Delta than Alpha, and lower still against Omicron 315 (Table 3, Supplementary Table 8). Our study reports efficacy over time since second dose against 316 the Alpha variant. Note the predicted vaccine efficacy for a reference individual reported in Table 317 3 and Figure 5 was slightly higher than the mean vaccine efficacy across all individuals (Fig. 3), 318 primarily because the mean vaccine efficacy averaged over all individuals including those who 319 had a shorter dose interval than 12 weeks. We predicted a slightly higher vaccine efficacy against 320 symptomatic infection with the Alpha variant after two doses of ChAdOx1 nCoV-19 (Table 3, 321 Fig. 5) than Andrews et al. (2022a) in all age groups, although confidence intervals overlapped 322

[13]. Other studies were conducted at least partly in periods where the Delta or Omicron variants 323 were dominant, and generally reported lower vaccine efficacy. Reported efficacy varied notice-324 ably between studies (Table 3, Supplementary Table 8). Differences in results between studies 325 may be due to different proportions of circulating variants, rates of asymptomatic swabbing, and 326 characteristics of the study populations, as well as the depletion of susceptibles bias, and previ-327 ously mentioned biases due to unmeasured confounding. Our results against the Alpha variant, 328 calculated on data from a randomised single-blinded study, are free from bias due to unmeasured 329 confounding. 330

Our data was collected in a period when the Alpha variant was dominant, and considered in-331 dividuals without prior infection who received two doses of vaccine. In contrast, the Omicron 332 variant is currently dominant, and many individuals have received three or more doses of vaccine 333 and been previously infected. Therefore our results may not be directly applicable to current 334 and future situation. To aid with this, we performed a supplementary analysis extrapolating our 335 results to examine what the efficacy over time since second dose might have been, in the hypo-336 thetical scenario where the study was conducted in the Omicron BA.4/5 period. The analysis 337 suggests a weak initial protection against Omicron BA.4/5, waning to negligible protection after 338 6 months. See the Supplementary Information (Sections 1.4.6, 2.1, 3, Supplementary Fig. 11) 339 for further details. 340

We further reported covariate effects on vaccine efficacy, although this analysis lacked power. We 341 observed lower vaccine efficacy for individuals with shorter intervals between the second dose; 342 results from previous studies have provided varying degrees of evidence for this [40, 14, 13]. 343 We reported lower VE in older individuals after around 3 months since the second dose (Fig. 344 5, Supplementary Fig. 10), with overlapping credible intervals. Faster waning [13] and lower 345 VE [37, 16] have been previously observed in older individuals. However, these effects were not 346 observed in all groups in the Andrews et al. study, with non-significant effects in the opposite 347 direction observed in some groups [13], and the Nordström et al. age estimates were unadjusted 348 and likely confounded due to different vaccines being given to different age groups [37]. Another 349 observational study observed higher efficacy in individuals aged 80+ years than 50-79, while 350 suggesting this could be confounded by clinical risk [40]. Hence further research on the effect 351 of age on vaccine efficacy is necessary. We did not observe a difference in vaccine efficacy for 352 individuals with comorbidites, although some prior studies suggest a lower VE in clinically vul-353 nerable individuals [16, 37, 13]. 354

355

| Paper | Vaccine vaccine ini /control ce | | Account for informative censoring at infection | Random individual slopes | Antibody type | Time of reported peak antibodies | Two-dose /booster /prior infection | Peak anti-spike IgG antibody level (BAU/mL) | Antibody half-life (days) | Covariates related to increased peak antibody levels | Covariates related to slower antibody decay |
|--------------------------------|------------------------------------|--------------|---|--------------------------------|-------------------|---|--|--|---|---|---|
| Wei et al. (2022) [9] | ChAdOx1 nCoV-19 BNT162b2* | x | x | V | Anti-spike IgG | 21 days post second dose | Two-dose | 184 (183, 185) | Mean 79 (78, 80) | Older age Female Non-white No LTHC Prior infection Healthcare worker Longer dose interval More deprivation | Younger age White No LTHC |
| Aldridge et al. (2022) [41] | ChAdOx1 nCoV-19 BNT162b2* | x | x | x | Anti-spike IgG | 28 days post second dose | Two-dose | - | 105.9 | None | None |
| Wei et al. (2023) [10] | ChAdOx1 nCoV-19 BNT162b2 | x | x | V | Anti-spike IgG | 21 days post second dose | Booster: BNT162b2 mRNA-1273 Infection | - | $\begin{array}{c} 78 \ (72, \ 86) \\ 63 \ (61, \ 66) \\ 96 \ (80, \ 119) \end{array}$ | Younger age Longer dose interval | Not reported |
| Our analysis | ChAdOx1 nCoV-19 | \checkmark | ✓ | ✓ | Anti-spike IgG | 28 days post second dose | Two-dose | 217 (208, 227) | Median 74 (69, 79) | Younger age (18-69) Non-white Longer dose interval Not HCW | $\begin{array}{l} {\rm Male} \\ {\rm BMI} < \!\! 30 \ \rm kg/m^2 \end{array}$ |

Table 2: Comparison of methods and results with previous studies of antibody level waning

We include studies of two doses of the ChAdOx1 nCoV-19 vaccine, and studies after a subsequent booster vaccine, focussing on anti-spike IgG antibody waning. Results are given with 95% confidence intervals or 95% credible intervals, depending on the paper. We report covariate effects where the null effect is not included in the 95% interval. HCW = healthcare worker, LTHC = long-term health condition. *We do not report these results here, see the original paper.

17

| Paper | Primary course vaccine | Dominant variant | Two-dose /booster /prior infection | Study design | Randomised vaccine /control assignment | Baseline comparator | Outcome | Location of result in paper | Group | Weeks since dose | Vaccine efficacy (%) |
|----------------------------------|--|----------------------------------|--|-----------------------------------|---|------------------------|----------------------------------|-----------------------------------|--|--|---|
| Our analysis† | ChAdOx1 nCoV-19 | Alpha | Two dose | Randomised Controlled Trial | √ | Unvaccinated | Symptomatic | Fig. 5 | Age 18-55 Age 56-69 Age 70+ | $5 \\ 10 \\ 20 \\ 26 \\ 5 \\ 10 \\ 20 \\ 26 \\ 5 \\ 10 \\ 20 \\ 26 \\ 26 \\ $ | $\begin{array}{c} 93.1 \ (81.6, \ 97.6) \\ 89.0 \ (76.6, \ 95.1) \\ 77.7 \ (64.5, \ 85.7) \\ 70.0 \ (55.0, \ 78.5) \\ 91.8 \ (80.0, \ 97.0) \\ 88.1 \ (76.1, \ 94.7) \\ 78.5 \ (66.3, \ 88.0) \\ 72.2 \ (57.2, \ 83.1) \\ 90.7 \ (78.8, \ 96.4) \\ 84.7 \ (73.0, \ 92.4) \\ 69.9 \ (54.5, \ 80.4) \\ 61.3 \ (38.1, \ 73.6) \end{array}$ |
| | | | | | | | Any infection | Supp. Fig. 10 | Age 18-55 Age 56-69 Age 70+ | $5 \\ 10 \\ 20 \\ 26 \\ 5 \\ 10 \\ 20 \\ 26 \\ 5 \\ 10 \\ 20 \\ 26 \\ 3 \\ 10 \\ 20 \\ 26 \\ 3 \\ 10 \\ 20 \\ 26 \\ 3 \\ 10 \\ 20 \\ 26 \\ 3 \\ 10 \\ 10 \\ 20 \\ 26 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 1$ | $\begin{array}{c} 84.3 \ (70.6, 91.8) \\ 77.2 \ (62.7, 86.1) \\ 60.5 \ (46.1, 70.1) \\ 50.6 \ (34.8, 60.1) \\ 81.8 \ (68.3, 90.4) \\ 75.6 \ (62.4, 85.3) \\ 61.6 \ (48.0, 73.7) \\ 53.4 \ (37.0, 66.5) \\ 79.9 \ (66.4, 89.0) \\ 70.4 \ (57.6, 80.9) \\ 50.4 \ (34.2, 62.8) \\ 40.1 \ (18.4, 53.8) \end{array}$ |
| Andrews et al. (2022a) [13] | ChAdOx1 nCoV-19 BNT162b2* | Alpha Delta* | Two dose | Test-negative | x | Unvaccinated | Symptomatic | Table S11 | Age 16+ Age 40-64 Age 65+ | 2-9 10+ 2-9 2-9 | 82.4 (79.6, 84.7) 76.2 (49.8, 88.7) 81.7 (76.0, 86.1) 88.2 (82.2, 92.1) |
| Nordström et al. (2022) [37] | ChAdOx1 nCoV-19 BNT162b2* mRNA-1273* | Alpha and Delta (Combined) | Two dose | Cohort | x | Unvaccinated | Any inection | Table 2 | Alpha, Delta and all ages combined | $\begin{array}{c} 2\text{-}4 \\ 4\text{-}9 \\ 9\text{-}17 \\ \geq 17 \end{array}$ | $\begin{array}{c} 68 \ (58, \ 70) \\ 49 \ (28, \ 64) \\ 41 \ (29, \ 51) \\ -19 \ (-98, \ 28) \end{array}$ |
| Skowronski et al. (2022) [14] | ChAdOx1 nCoV-19 BNT162b2* mRNA-1273* Mixed schedules* | Alpha Delta | Two dose | Test-negative | x | Unvaccinated | Any inection Hospitalisation* | Supp. Table 12 | Quebec (Alpha and Delta) British Columbia (Delta) | 4-7 8-11 20-23 24-27 4-7 8-11 20-23 24-27 | $\begin{array}{c} 90 \ (84, 94) \\ 85 \ (81, 88) \\ 70 \ (64, 75) \\ 56 \ (43, 65) \\ 77 \ (71, 82) \\ 76 \ (73, 79) \\ 74 \ (70, 78) \\ 67 \ (48, 80) \end{array}$ |

Table 3: Comparison of methods and results with previous vaccine efficacy waning studies, against the Alpha and Delta variants

We include studies of two doses of the ChAdOx1 nCoV-19 vaccine, prior to the Omicron variant. Results are given with 95% confidence intervals or 95% credible intervals, depending on the paper. Results are presented for different age groups, where appropriate. *We do not report these results here, see the original paper. [†]We report here the predicted vaccine efficacy for a reference individual in the given age group, with covariates: female, white, no comorbidities, BMI<30 kg/m², \geq 12 week interval, not a healthcare worker, standard dose.

Our study has several limitions. Our results may not be directly applicable to current and 356 future populations, for four reasons. Firstly dominant variants have changed from B.1.177 and 357 Alpha (B.1.1.7) variants when our data was collected, to the Omicron variant today. Secondly 358 individuals in the study were SARS-CoV-2 naïve, results will likely differ in individuals with 359 prior infection [10]. Thirdly individuals in the study received two doses of ChAdOx1 nCoV-19, 360 whereas three or more doses of different vaccines have been given in many populations. 361 Fourthly the study population differs from the general population, being predominantly white, 362 18-55 years old and including mostly healthcare workers. For these reasons our results are 363 unlikely to transfer directly to the general population today, although qualitative aspects of our 364 results, and our methods, remain relevant. We further only consider the effect of anti-spike IgG 365 binding antibodies, and do not measure neutralising antibodies or cellular immune responses. 366 It may be that the protection conferred by other immune responses depends on the antibody 367 level, or changes with time, whereas we assumed a constant effect. We did not consider the 368 effect on risk of hospitalisation, severe disease and death due to insufficient data. Fewer 369 antibody observations were available at the later timepoints (PB90 and PB182 study visits), 370 causing greater uncertainty in our estimates at later times. We assumed a 7 day gap from 371 exposure to reported infection; deviation from this assumption may introduce a small bias to 372 our analysis. We did not account for the change in dominant variant from B.1.177 to B.1.1.7 373 (Alpha) during the study, however we expect the impact of this on VE to be negligible [42]. 374 The dose of virus that individuals were exposed to may have varied throughout the study, as 375 social distancing policies changed. Further, viral load is likely to have varied between 376 individuals depending on previous exposure to COVID-19, and the variant to which they were 377 exposed. We have not accounted for differences in viral load or dose of virus in this analysis. 378 In summary, we report correlates of protection against any COVID-19 infection and 379 symptomatic infection from a randomised COVID-19 vaccine study, using binding antibody 380 responses at the time of exposure. We further report vaccine efficacy waning over time, 381 antibody waning over time, and associated covariate effects. We use a joint model which 382 accounts for antibody measurement error, the waning of antibody levels over time, and 383 censoring of antibody observations at COVID-19 infection. This may reduce bias and increase 384 power in the analysis compared with previous approaches. 385

386 Methods

³⁸⁷ Study description

We analysed data from COV002 (registration NCT04400838), a phase 2/3 randomized

³⁸⁹ single-blind vaccine efficacy (VE) trial conducted across 19 sites in the United Kingdom. A full

³⁹⁰ description of the trial including immunogenicity, efficacy, and safety data, and the protocol has

³⁹¹ been previously published [32, 33, 34, 42]. An analysis of immune correlates of protection,

³⁹² relating antibody measurements 28 days after the second dose with protection against

³⁹³ infection, was previously published [1].

³⁹⁴ This study was approved in the United Kingdom by the Medicines and Healthcare products

Regulatory Agency (MHRA), reference 21584/0428/001–0001, and the South-Central Berkshire

³⁹⁶ Research Ethics Committee, reference 20/SC/0179. All participants provided informed consent.

³⁹⁷ Participants in the study were randomized to receive ChAdOx1 nCoV-19 (AZD1222) or a

³⁹⁸ MenACWY control vaccine. The randomization ratio (ChAdOx1 nCoV-19:MenACWY)

differed by study cohort, and was either 1:1, 5:1, or 3:1. Open label groups are not included in

400 this analysis.

401 Study endpoints and outcomes

⁴⁰² Participants were sent weekly reminders to contact their study site if they experienced any of

the primary symptoms of COVID-19 (fever \geq 37.8 °C; cough; shortness of breath; anosmia or

 $_{404}$ $\,$ ageusia) and were then assessed in clinic, by taking a nose and throat swab by a nucleic acid

⁴⁰⁵ amplification test (NAAT). In addition, participants were asked to complete a nose and throat ⁴⁰⁶ swab at home each week.

⁴⁰⁷ The outcomes for this analysis were (1) primary symptomatic COVID-19 infection, that is a

 $_{408}$ $\,$ nucleic acid amplification test positive (NAAT+) swab with at least one qualifying symptom,

(2) any COVID-19 infection, that is any NAAT+ swab.

All endpoints were evaluated by a blinded independent clinical review committee. The date of onset of infection was determined by the committee, as the earliest time at which there was

evidence of infection. Evidence included NAAT+ swabs and self-reported symptoms based on
 telephone contact and study visits.

414 Antibody measurements

A proportion of serum samples from vaccine recipients at the PB28, PB90 and PB182 study 415 visits were tested for anti-SARS-CoV-2 Spike IgG in a single laboratory assay. For PB28 416 samples, all NAAT+ cases were tested if sample volume allowed, and a proportion of non-cases 417 were tested. Samples were tested blinded to case status. The data from noncases was obtained 418 first, and consisted mainly of the samples processed for the initial application for emergency 419 use, which needed 15% of samples included in the efficacy cohort to be processed on validated 420 assays. Subsequent to this PB28 samples from NAAT+ cases were sent for testing as they 421 occurred, if not already including the 15%. A proportion of those participants with samples 422 tested at PB28 were additionally tested at either PB90 only, or PB90 and PB182. We assume 423 the samples to be missing at random, i.e. the missingness depended only on factors observed in 424 the study. To account for the missing data, factors associated with sample availability were 425 included as covariates in the model for antibody decay (see 'Antibody decay model' below). 426 Anti-SARS-CoV-2 Spike IgG was measured by a multiplex immunoassay on the MSD platform 427 at PPD Laboratories. The assay sequences were based on the ancestral sequences from Wuhan, 428

429 China. Assay validation included precision and ruggedness, dilutional linearity, selectivity, and

- ⁴³⁰ relative accuracy for each SARS-CoV-2 antigens. Post-validation studies for stability and for
- 431 conversion to the WHO standard, as well as the establishment of a cut-point, were performed.
- ⁴³² The lower limit of quantification (LLOQ) for anti-spike IgG was 33 AU/mL (0.21 BAU/mL).
- 433 We excluded 8 anti-spike IgG results as outliers three results at PB28 and four at PB90 whose

 $_{\rm 434}$ $\,$ anti-spike IgG levels were especially low, and one results at PB90 whose levels were especially

⁴³⁵ high (Supplementary Table 3, Supplementary Fig. 2). The individuals from whom these

436 samples were taken, and any other antibody measurements are included in the analysis - only

the outlying antibody measurements are excluded. Outliers were excluded as they may bias the
results [43].

⁴³⁹ The assay was analysed in its original scale. Results were then converted to the WHO

international standard units, binding antibody units per mL (BAU/mL), by multiplying by a

- 441 conversion factor supplied by the laboratory. The anti-spike IgG conversion factor from
- arbitrary units per mL (AU/mL) to WHO standard binding antibody units per mL (BAU/mL)

was 0.00645 (95%) confidence interval (CI): 0.00594, 0.00701). We did not apply the CI, as it

- represents the uncertainty due to measurement error in the assay, and our antibody model
- ⁴⁴⁵ already accounts for this.

446 Study design

 $_{\rm 447}$ $\,$ We included a subset of participants in the COV002 trial in our study, who met the following

 $_{448}$ $\,$ eligibility criteria: received two doses of ChAdOx1 nCoV-19 or MenACWY control vaccine,

- baseline seronegative to the SARS-CoV-2 N protein at first vaccination, and followed up to at
- $_{450}$ least day 21 post second vaccination with no evidence of prior infection. Vaccinated
- ⁴⁵¹ participants received a first and second dose: either two standard doses, low dose followed by
- 452 standard dose, or two low doses. Nine participants who received mixed schedules in error (one

dose of ChAdOx1 nCoV-19 and one dose of MenACWY control) were excluded from the

⁴⁵⁴ analysis (Supplementary Fig. 1). One control individual had missing BMI, we imputed this ⁴⁵⁵ with the mean value in the study.

⁴⁵⁶ Participants were considered at-risk of the study event from day 21 post second dose. The

- 457 at-risk period ended at the first of: the onset of COVID-19 infection, withdrawal, unblinding,
- ⁴⁵⁸ or the analysis cut-off date 30 June 2021. Antibody levels were assumed to relate to risk of
- ⁴⁵⁹ infection 7 days later, to account for the gap between first being exposed to COVID-19 until a

case is reported in the trial. Thus antibody measurements are excluded if taken prior to 14

- 461 days after the second dose, after the end of the at-risk period, or less than 7 days before the
- 462 end of the at-risk period.

⁴⁶³ Participants who tested NAAT+ during the at-risk period were defined as cases, those who also

⁴⁶⁴ had at least one qualifying symptom were defined as symptomatic cases, while those who did

⁴⁶⁵ not return a positive test during the at-risk period were defined as non-cases.

466 Statistical Analysis

We modelled antibody decay and the risk of COVID-19 infection in a two-stage joint model for 467 longitudinal and survival data. Joint models are a popular method to consider the relationship 468 between a longitudinal biomarker and the risk of a health outcome, especially in studies of 469 disease progression such as HIV and cancer trials [8]. We employed a two-stage multiple 470 imputation approach to overcome convergence issues that arose when attempting to fit a full 471 joint model. A mathematical formulation of the model, and an explanation of how the 472 two-stage method approximates a Bayesian joint model, are given in the Supplementary 473 Methods. 474

Antibody decay model In the first stage, we fit a log-linear Bayesian mixed effects model 475 to the antibody decay after vaccination for ChAdOx1 nCoV-19 recipients (see Supplementary 476 Methods). The Bayesian approach easily accounts for the complex structure of the data and 477 the model, including missing antibody observations for some individuals, and unknown true 478 antibody levels which change over time. We first standardised the data; after running the 479 model we transformed the parameters back to the scale of the original dataset. The log 480 antibody observations were assumed to have t-distributed zero-mean random error, with 4 481 degrees of freedom and unknown scale (Supplementary Methods). The latent true log antibody 482 values were assumed to decay linearly from 14 days post second dose. The model included an 483 effect on both the peak antibody response (intercept) and rate of decay (slope) due to the 484 following covariates: age group (18-55 years, 56-69 years, 70+ years), sex (female, male), 485 ethnicity (white, non-white), comorbidity (none, comorbidity), BMI ($<30 \text{ kg/m}^2, >30$), time 486 interval between first and second dose (≥ 12 weeks, 9-11 weeks, 6-8 weeks, <6 weeks), 487 healthcare worker (HCW) status (not a HCW, HCW facing <1 COVID-19 patient per day, 488 HCW facing ≥ 1 COVID-19 patient per day), initial dose (standard dose, low dose). The 489 probability of missing antibody data was observed to be related to whether an individual tested 490 positive and their follow-up time. To account for this, we also included covariate effects on the 491 intercept and slope due to: (i) returning a positive test during the study, (ii) being primary 492 symptomatic, and (iii) the Nelson–Aalen estimate of cumulative hazard for any COVID-19 493 infection in the vaccine group, as previously suggested [44]. We allowed a random intercept and 494 slope for each individual, as well as a correlation between the random effects. The slopes were 495 required to be negative, by applying the negative of the exponential function to the slope 496 parameter. This was done to avoid convergence issues in the risk of infection model due to 497 exponentially increasing antibody levels. The model predicts antibody trajectories for all 498 vaccinated individuals, with appropriate uncertainty. The model was fit using Hamiltonian 499 Monte Carlo in Stan [45]. Four chains were run, each of 20,000 iterations. The first 5,000 500 iterations were discarded as burn-in. Convergence was checked by ensuring the Rhat 501 convergence diagnostic (potential scale reduction factor) was less than 1.01 [46]. See the 502 503 Supplementary Information (Section 2.3) for the reported computation time.

Risk of infection model In the second stage, we fit a Cox model to the time until 504 COVID-19 onset (either primary symptomatic COVID-19 infection or any COVID-19 505 infection), using the output from the antibody model to predict the risk of infection. We 506 employed multiple imputation [31], which accounts for the uncertainty in the predicted 507 antibody levels in our estimation of the hazard (instantaneous risk) for infection (see 508 Supplementary Methods). A previously published multiple imputation-based joint model was 509 shown to reduce bias compared with single imputation "naïve" two-stage approaches [25]. We 510 first sampled 60,000 antibody trajectories from the first stage for each vaccinated individual, 511 from which we imputed the predicted antibody levels at each relevant time. For each sample, 512 we fit a Cox model for the time to infection. The baseline hazard varies with calendar time, to 513 account for the changing rates of COVID-19 in the population during the pandemic, and is 514 stratified by study site, to account for different rates across geographic regions. The hazard for 515 a given vaccinated individual i at time t then depends on the effect γ of their imputed antibody 516 levels $A_i(t-7)$ at time t-7, and a direct effect due to vaccination ζ , unrelated to antibody 517 levels. We further included covariate effects which may affect the risk of infection: age group 518 (18-55 years, 56-69 years, 70+ years), sex (female, male), ethnicity (white, non-white), 519 comorbidity (none, comorbidity), BMI ($<30 \text{ kg/m}^2$, >30), healthcare worker (HCW) status 520 (not a HCW, HCW facing <1 COVID-19 patient per day, HCW facing \geq 1 COVID-19 patient 521 per day). The hazard for a given control individual i at time t depends only on the baseline 522 hazard and covariates, we assume no antibody or vaccine effect for control individuals. 523 For each Cox model, we then drew from the asymptotic distribution of the maximum likelihood 524 estimators, to approximate a Bayesian posterior with diffuse improper priors [47]. We 525 combined this draw with the corresponding antibody model individual intercepts and slopes to 526 form a draw from the approximate joint distribution. Quantities of interest, such as vaccine 527 efficacy, can then be calculated from each draw. Posterior medians and 95% CrIs are calculated 528 based on quantiles of the posterior samples. 529

Calculating vaccine efficacy Vaccine efficacy (VE) at a given antibody level A is then
 calculated as 1 minus the hazard ratio between a vaccinated individual with that level of
 antibody, and a control individual with matching covariates.

$$VE(A) = 1 - \exp(\gamma A + \zeta)$$
(1)

with γ the antibody effect and ζ the direct effect due to vaccination. Antibody level at a given VE is defined by the inverse of Eq (1). For individuals i = 1, ..., n in the vaccine arm, let $A_i(t-7)$ be the latent antibody level at time t-7. Then the mean VE at time t is the mean VE among all the latent antibody levels of vaccinated individuals at time t-7.

$$VE(t) = \frac{1}{n} \sum_{i=1}^{n} VE(A_i(t-7)) = 1 - \frac{1}{n} \sum_{i=1}^{n} \exp(\gamma A_i(t-7) + \zeta)$$
(2)

⁵³⁷ The *q*th quantile of VE at time *t*, $VE_q(t)$, is equal to the VE at the *q*th antibody quantile ⁵³⁸ $A_q(t)$, $VE_q(t) = 1 - \exp(\gamma A_q(t) + \zeta)$.

Calculating covariate effects on vaccine efficacy To calculate covariate effects on 539 vaccine efficacy, we predicted efficacy in new individuals with given covariate values. Note the 540 event indicators and Nelson-Aalen (N-A) estimate of cumulative hazard for a new individual 541 are unknown, as they depend on the infection outcome. We first built an imputation model to 542 sequentially impute the missing event indicators (infection, symptomatic) and N-A estimate, 543 which appear in the longitudinal antibody model, given the known covariates. We imputed 544 these missing covariates n times. For each set of imputed covariates, we drew from the 545 predictive distribution of antibody trajectories for a new individual with the given covariate 546 values, $A_j^{\text{pred}}(t), j = 1, \dots, n$. We then averaged these to calculate the mean risk of infection 547 given the known covariate values 548

$$VE(t) = \frac{1}{n} \sum_{j=1}^{n} VE(A_j^{\text{pred}}(t)) = 1 - \frac{1}{n} \sum_{j=1}^{n} \exp(\gamma A_j^{\text{pred}}(t) + \zeta)$$
(3)

Software Data analysis was performed in R version 4.3.1 [48], using RStudio [49], and
relying extensively on the following packages: survival [50], RStan [51], snowfall [52], ggplot2
[53]. RColorBrewer [54] and tidyr [55] were also used. Hamiltonian Monte Carlo algorithms
were run in Stan [45] via the R package RStan [51].

553 Data availability

Anonymized data will be made available via the Vivli platform https://vivli.org/. Source data for the figures are provided with this paper where possible.

556 Code availability

557 The code used for the analysis is available at GitHub repository

558 https://github.com/danphillipsstats/COVID-joint-model-CoP.

559 References

- ⁵⁶⁰ [1] Feng, S. et al. Correlates of protection against symptomatic and asymptomatic
- 561 SARS-CoV-2 infection. *Nature Medicine* **27**, 2032–2040 (2021).
- [2] Benkeser, D. et al. Immune correlates analysis of a phase 3 trial of the AZD1222
- ⁵⁶³ (ChAdOx1 nCoV-19) vaccine. *npj Vaccines* **8**, 36 (2023).

- [3] Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
- ⁵⁶⁵ efficacy clinical trial. *Science* **375**, 43–50 (2022).
- Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26. COV2. S dose
 vaccine efficacy clinical trial. Nature Microbiology 7, 1996–2010 (2022).
- ⁵⁶⁸ [5] Fong, Y. *et al.* Immune correlates analysis of the PREVENT-19 COVID-19 vaccine
 ⁵⁶⁹ efficacy clinical trial. *Nature Communications* 14, 331 (2023).
- [6] Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine
 BNT162b2. Nature Communications 14, 4575 (2023).
- [7] Zhang, B. *et al.* Omicron COVID-19 immune correlates analysis of a third dose of
 mRNA-1273 in the COVE trial. *medRxiv* 2023–10 (2023).
- [8] Ibrahim, J. G., Chu, H. & Chen, L. M. Basic concepts and methods for joint models of
 longitudinal and survival data. *Journal of Clinical Oncology* 28, 2796 (2010).
- [9] Wei, J. *et al.* Antibody responses and correlates of protection in the general population
 after two doses of the ChAdOx1 or BNT162b2 vaccines. *Nature Medicine* 28, 1072–1082
 (2022).
- ⁵⁷⁹ [10] Wei, J. *et al.* Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster ⁵⁸⁰ vaccination or breakthrough infection in the UK. *Nature Communications* **14**, 2799 (2023).
- [11] Follmann, D. *et al.* Examining protective effects of SARS-CoV-2 neutralizing antibodies
 after vaccination or monoclonal antibody administration. *Nature Communications* 14, 3605 (2023).
- ⁵⁸⁴ [12] Hu, P., Tsiatis, A. A. & Davidian, M. Estimating the parameters in the Cox model when ⁵⁸⁵ covariate variables are measured with error. *Biometrics* 1407–1419 (1998).
- [13] Andrews, N. *et al.* Duration of protection against mild and severe disease by Covid-19
 vaccines. New England Journal of Medicine 386, 340–350 (2022).
- [14] Skowronski, D. M. *et al.* Two-dose severe acute respiratory syndrome coronavirus 2
 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative
 design studies from British Columbia and Quebec, Canada. *Clinical Infectious Diseases* **75**, 1980–1992 (2022).
- ⁵⁹² [15] Katikireddi, S. V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against
- ⁵⁹³ COVID-19 hospital admissions and deaths over time: a retrospective, population-based ⁵⁹⁴ cohort study in Scotland and Brazil. *The Lancet* **399**, 25–35 (2022).
- [16] Menni, C. *et al.* COVID-19 vaccine waning and effectiveness and side-effects of boosters: a
 prospective community study from the ZOE COVID Study. *The Lancet Infectious Diseases* 22, 1002–1010 (2022).

- ⁵⁹⁸ [17] Horne, E. M. *et al.* Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines ⁵⁹⁹ over six months since second dose: OpenSAFELY cohort study using linked electronic
- 600 health records. BMJ **378** (2022).
- [18] Andrews, N. *et al.* Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- [19] Andrews, N. *et al.* Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nature Medicine* **28**, 831–837 (2022).
- [20] Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the
 test-negative study design for assessment of influenza vaccine effectiveness. *American Journal of Epidemiology* 184, 345–353 (2016).
- [21] Westreich, D. & Hudgens, M. G. Invited commentary: beware the test-negative design.
 American Journal of Epidemiology 184, 354–356 (2016).
- [22] Fleming, T. R., Prentice, R. L., Pepe, M. S. & Glidden, D. Surrogate and auxiliary
 endpoints in clinical trials, with potential applications in cancer and AIDS research.
 Statistics in Medicine 13, 955–968 (1994).
- [23] Tsiatis, A. A. & Davidian, M. Joint modeling of longitudinal and time-to-event data: an
 overview. *Statistica Sinica* 809–834 (2004).
- Gould, L. A. *et al.* Joint modeling of survival and longitudinal non-survival data: current
 methods and issues. Report of the DIA Bayesian joint modeling working group. *Statistics in Medicine* 34, 2181–2195 (2015).
- [25] Moreno-Betancur, M. *et al.* Survival analysis with time-dependent covariates subject to
 missing data or measurement error: Multiple Imputation for Joint Modeling (MIJM).
 Biostatistics 19, 479–496 (2018).
- [26] Néant, N. et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in
 hospitalized patients from the French COVID cohort. Proceedings of the National
 Academy of Sciences 118, e2017962118 (2021).
- [27] Tong-Minh, K. *et al.* Joint modeling of repeated measurements of different biomarkers
 predicts mortality in COVID-19 patients in the Intensive Care Unit. *Biomarker Insights* **17**, 11772719221112370 (2022).
- [28] Chen, X. et al. A predictive paradigm for COVID-19 prognosis based on the longitudinal
 measure of biomarkers. Briefings in Bioinformatics 22, bbab206 (2021).
- [29] Fu, R. & Gilbert, P. B. Joint modeling of longitudinal and survival data with the Cox
 model and two-phase sampling. *Lifetime Data Analysis* 23, 136–159 (2017).

| 631 632 633 | [30] | Ibrahim, J. G., Chen, MH. & Sinha, D. Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine trials. <i>Statistica Sinica</i> 863–883 (2004). |
|-------------------|------|--|
| 634 | [31] | Rubin, D. B. Multiple Imputation for Nonresponse in Surveys (Wiley, 1987). |
| 635 636 637 | [32] | Ramasamy, M. N. <i>et al.</i> Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>The Lancet</i> 396 , 1979–1993 (2020). |
| 638 639 640 | [33] | Voysey, M. <i>et al.</i> Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>The Lancet</i> 397 , 99–111 (2021). |
| 641 642 643 | [34] | Voysey, M. <i>et al.</i> Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>The Lancet</i> 397 , 881–891 (2021). |
| 644 645 646 | [35] | Flaxman, A. <i>et al.</i> Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>The Lancet</i> 398 , 981–990 (2021). |
| 647 648 | [36] | Henderson, R., Diggle, P. & Dobson, A. Joint modelling of longitudinal measurements and event time data. <i>Biostatistics</i> 1, 465–480 (2000). |
| 649 650 651 | [37] | Nordström, P., Ballin, M. & Nordström, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. <i>The Lancet</i> 399 , 814–823 (2022). |
| 652 653 654 | [38] | Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines. <i>American Journal of Epidemiology</i> 191 , 800–811 (2022). |
| 655 656 | [39] | Williams, L. R. <i>et al.</i> Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial. <i>medRxiv</i> 2024–02 (2024). |
| 657 658 | [40] | Amirthalingam, G. <i>et al.</i> Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in england. <i>Nature Communications</i> 12 , 7217 (2021). |
| 659 660 | [41] | Aldridge, R. W. <i>et al.</i> SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. <i>Nature Communications</i> 13 , 4869 (2022). |
| 661 662 663 | [42] | Emary, K. R. <i>et al.</i> Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. <i>The Lancet</i> 397 , 1351–1362 (2021). |

- [43] Li, N., Elashoff, R. M. & Li, G. Robust joint modeling of longitudinal measurements and
 competing risks failure time data. *Biometrical Journal: Journal of Mathematical Methods in Biosciences* 51, 19–30 (2009).
- ⁶⁶⁷ [44] White, I. R. & Royston, P. Imputing missing covariate values for the Cox model. *Statistics* ⁶⁶⁸ *in Medicine* **28**, 1982–1998 (2009).
- [45] Stan Development Team. Stan Modeling Language Users Guide and Reference Manual
 (2022). URL https://mc-stan.org.
- ⁶⁷¹ [46] Vehtari, A., Gelman, A., Simpson, D., Carpenter, B. & Bürkner, P.-C.
- Rank-normalization, folding, and localization: an improved R for assessing convergence of
 MCMC (with discussion). *Bayesian Analysis* 16, 667–718 (2021).
- [47] Sinha, D., Ibrahim, J. G. & Chen, M.-H. A Bayesian justification of Cox's partial
 likelihood. *Biometrika* 90, 629–641 (2003).
- [48] R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
 for Statistical Computing, Vienna, Austria (2023). URL https://www.R-project.org/.
- [49] RStudio Team. RStudio: Integrated Development Environment for R. RStudio, PBC.,
 Boston, MA (2020). URL http://www.rstudio.com/.
- [50] Therneau, T. M. A Package for Survival Analysis in R (2024). URL
 https://CRAN.R-project.org/package=survival. R package version 3.6-4.
- [51] Stan Development Team. RStan: the R interface to Stan (2024). URL
 https://mc-stan.org/. R package version 2.32.6.
- [52] Knaus, J. snowfall: Easier Cluster Computing (Based on 'snow') (2023). URL
- https://CRAN.R-project.org/package=snowfall. R package version 1.84-6.3.
- [53] Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag New York,
 2016). URL https://ggplot2.tidyverse.org.
- [54] Neuwirth, E. *RColorBrewer: ColorBrewer Palettes* (2022). URL
- https://CRAN.R-project.org/package=RColorBrewer. R package version 1.1-3.
- [55] Wickham, H., Vaughan, D. & Girlich, M. tidyr: Tidy Messy Data (2024). URL
- https://CRAN.R-project.org/package=tidyr. R package version 1.3.1.

692 Acknowledgements

- ⁶⁹³ We thank Geoff Nicholls for a helpful discussion suggesting the use of Bayesian cut posteriors,
- ⁶⁹⁴ which led us to developing the Bayesian multiple imputation method.

Author contributions

All authors contributed to the conceptualisation of the study. SF, AJP and MV contributed to data collection. DJP, MDC and DS developed the statistical methods. DJP conducted the statistical analysis. The project was jointly supervised by MDC and DS. The first draft of the report was written by DJP and reviewed by MDC and DS. All authors critically reviewed and approved the final version.

701 Funding

The collection of the data used in this work was supported by the UK Research and Innovation

⁷⁰³ (MC_PC_19055), Engineering and Physical Sciences Research Council (EP/R013756/1),

⁷⁰⁴ National Institute for Health Research (COV19 OxfordVacc-01), Coalition for Epidemic

⁷⁰⁵ Preparedness Innovations (Outbreak Response To Novel Coronavirus (COVID-19)), National

⁷⁰⁶ Institute for Health Research Oxford Biomedical Research Centre (BRC4 Vaccines Theme),

⁷⁰⁷ Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China (2018-I2M-2-

⁷⁰⁸ 002), Thames Valley and South Midlands NIHR Clinical Research Network. DJP discloses

⁷⁰⁹ support for the research of this work from the Engineering and Physical Sciences Research

 $_{710}$ Council (EP/W523781/1). The views expressed in this publication are those of the authors and

not necessarily those of the NIHR or the UK Department of Health and Social Care.

712 AstraZeneca reviewed the final manuscript but the academic authors retained editorial control.

713 Other funders had no role in study design, data collection and analysis, or decision to publish.

714 Competing interests

⁷¹⁵ SF, AJP and MV are contributors to intellectual property licensed by Oxford University

716 Innovation to AstraZeneca. AJP is Chair of the UK Department of Health and Social Care's

717 (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in

⁷¹⁸ discussions on COVID-19 vaccines. The authors report no other conflicts of interest.

T19 Ethics approval

The COV002 study was approved in the United Kingdom by the Medicines and Healthcare

⁷²¹ products Regulatory Agency (MHRA), reference 21584/0428/001 0001, and the South-Central

Berkshire Research Ethics Committee, reference 20/SC/0179. All participants provided

⁷²³ informed consent.

724 Materials & Correspondence

⁷²⁵ Correspondence to Daniel J. Phillips, email: daniel.phillips@stats.ox.ac.uk.